FIG. 1



α-GalCer
Insulin-B-peptide-incorporated
α-GalCer-containing liposome
OVA-peptide-incorporated
α-GalCer-liposome
α-GalCer-liposome
Insulin-B-peptide-incorporated
liposome

FIG. 2




90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Incidence of diabetes (%)
Group receiving no drug
Group receiving OVA-peptide-incorporated
α-GalCer-liposome
Group receiving
insulin-B-peptide-incorporated liposome
NOD mice
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Intraperitoneal administration
twice a week to mice between
the age of 4 and 8 weeks, of
100 μl of sample for
administration
Group receiving
insulin-B-peptide-incorporated
α-GalCer-liposome

FIG. 3



No: Group receiving no drug
iB-GC-lipo: Group receiving insulin-B-peptide-incorporated α-GalCer-liposome
iB-lipo: Group receiving insulin-B-peptide-incorporated liposome
GC-lipo: Group receiving α-GalCer-liposome
GC: Group receiving α-GalCer solution

FIG. 4




Insulin-incorporated
α-GalCer-liposome
NOD mice
4 5 6 7
Administration twice a week to mice between the age of 4 and 8 weeks, of insulin-incorporated α-GalCer-liposome
Incidence of diabetes (%)
0
10
20
30
40
50
60
70
80
8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Weeks
Group receiving no drug
Tail vein administration group
Subcutaneous administration group
Intraperitoneal administration group

FIG. 5


Percentage (%) of NRP-V7 (+) cells
(pancreatic β cell-specific CTLs)
2.5
2.0
1.5
1.0
0.5
0.0
Group receiving no drug
Group receiving insulin-incorporated
α-GalCer-liposome
Group receiving
insulin-incorporated liposome
Group receiving
α-GalCer-liposome